You are here: Industry Insights > EW

News List

Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
April 28, 2025
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
April 25, 2025
HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
Top 10 Sales Volume of New Drugs of Traditional Chinese Medicine: Behind the Numbers - Only 2 Out of 29 Surpassed RMB 100 Million in Sales Xiao Yan
March 14, 2025
From 2016 - 2024, TCM new drugs made progress but lagged in sales. This article analyzes reasons and explores future directions.
Senolytics: The New Hope for Slowing Aging Nurah Ekhlaque
March 04, 2025
A Breakthrough in Slowing Aging & Longevity
Top Generalizable Antivirals for Stockpiling in Emergencies: A Review and Gap Analysis David Orchard-Webb
February 06, 2025
Reviews top generalizable antivirals for emergency stockpiling, analyzes their pros & cons, and points out gaps in antiviral stockpile.
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
New FDA Regulations in the Year 2024 Muhammad Asim Niazi
January 07, 2025
The United States FDA regulates pharma drug products manufactured or marketed in the United States. There are many different functions of the FDA, and one of them is devising new regulations.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
New Pathways for Innovation and Transformation of Local Pharmaceutical Companies Xiaobin
December 20, 2024
INNOVATION announced it will acquire 100% equity in CSPC Baike for up to RMB 7.6 billion, 10% in cash and 90% in shares.